Decreased survival after conversion to serum HER-2/neu positive.

被引：0
|
作者：
Lipton, A
Leitzel, K
Ali, SM
Demers, L
Harvey, HA
Chaudri-Ross, H
Lang, R
Hackl, W
Hamer, P
Carney, W
机构：
[1] W Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VA Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Oncogene Sci Bayer Diagnost, Cambridge, MA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2003年 / 82卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
508
引用
收藏
页码：S121 / S121
页数：1
相关论文
共 50 条
  • [21] Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
    Lipton, A
    Ali, SM
    Leitzel, K
    Demers, L
    Chinchilli, V
    Engle, L
    Harvey, HA
    Brady, C
    Nalin, CM
    Dugan, M
    Carney, W
    Allard, J
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (06) : 1467 - 1472
  • [22] HER-2/NEU AMPLIFICATION PREDICTS POOR SURVIVAL IN NODE-POSITIVE BREAST-CANCER
    BORG, A
    TANDON, AK
    SIGURDSSON, H
    CLARK, GM
    FERNO, M
    FUQUA, SAW
    KILLANDER, D
    MCGUIRE, WL
    CANCER RESEARCH, 1990, 50 (14) : 4332 - 4337
  • [23] The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer
    Schippinger, W
    Regitnig, P
    Bauernhofer, T
    Ploner, F
    Hofmann, G
    Krippl, P
    Wehrschütz, M
    Lax, S
    Carney, W
    Neumann, R
    Wernecke, KD
    Samonigg, H
    ONCOLOGY REPORTS, 2004, 11 (06) : 1331 - 1336
  • [24] Serum HER-2/neu conversion to positive at the time of cancer progression in metastatic breast patients treated with letrozole vs. tamoxifen.
    Lipton, A
    Leitzel, K
    Ali, SM
    Demers, L
    Harvey, HA
    Chaudri-Ross, HA
    Lang, R
    Hackl, W
    Hamer, P
    Carney, W
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 288S - 288S
  • [25] Serum HER-2/neu decline predicts improved response to trastuzumab-based therapy in patients with normal and elevated baseline serum HER-2/neu levels.
    Ali, S. M.
    Brault, D.
    Brown-Shimer, S.
    Carney, W.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Hamer, P.
    Harris, L.
    Leitzel, K.
    Kostler, W.
    Lotz, J-P
    Luftner, D.
    Pichon, M-F
    Thiel, R. P.
    Tse, C.
    Wheler, J.
    Lipton, A.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S90 - S90
  • [26] HER-2/neu testing guidelines
    Masood, S
    LABORATORY MEDICINE, 2000, 31 (03) : 129 - 130
  • [27] Her-2/neu and breast cancer
    Kaptain, S
    Tan, LK
    Chen, BY
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2001, 10 (03) : 139 - 152
  • [28] HER-2/neu in bladder carcinoma
    Tommasi, S
    Ditonno, P
    Sisto, MR
    Paradiso, A
    Gentile, A
    Ricco, R
    Schittulli, F
    Jacobellis, U
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (05) : 957 - 961
  • [29] Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice
    Jacob, Jennifer
    Radkevich, Olga
    Forni, Guido
    Zielinski, John
    Shim, David
    Jones, Richard F.
    Wei, Wei-Zen
    CELLULAR IMMUNOLOGY, 2006, 240 (02) : 96 - 106
  • [30] HER-2 therapy. HER-2/neu diagnostics in breast cancer
    Walter P Carney
    Kim Leitzel
    Suhail Ali
    Rainer Neumann
    Allan Lipton
    Breast Cancer Research, 9
12345